key: cord-0688885-h04zwcqa
authors: Fu, Wenyan; Lei, Changhai; Qian, Kewen; Ma, Zetong; Li, Tian; Lin, Fangxin; Zhang, Wei; Zhao, Jian; Hu, Shi
title: CAR Macrophages for SARS-CoV-2 Immunotherapy
date: 2020-08-20
journal: bioRxiv
DOI: 10.1101/2020.07.26.222208
sha: c4b469198e7c48b4e050112b370169d976b50af6
doc_id: 688885
cord_uid: h04zwcqa

Targeted therapeutics for the treatment of coronavirus disease 2019 (COVID-19), especially severe cases, are currently lacking. As macrophages have unique effector functions as a first-line defense against invading pathogens, we genetically armed human macrophages with chimeric antigen receptors (CARs) to reprogram their phagocytic activity against SARS-CoV-2. After investigation of CAR constructs with different intracellular receptor domains, we found that although cytosolic domains from MERTK (CARMERTK) did not trigger antigen-specific cellular phagocytosis or killing effects, unlike those from MEGF10, FcRγ and CD3ζ did, these CARs all mediated similar SARS-CoV-2 clearance in vitro. Notably, we showed that CARMERTK macrophages reduced the virion load without upregulation of proinflammatory cytokine expression. These results suggest that CARMERTK drives an ‘immunologically silent’ scavenger effect in macrophages and pave the way for further investigation of CARs for the treatment of individuals with COVID-19, particularly those with severe cases at a high risk of hyperinflammation.

The coronavirus disease 2019 (COVID-19) pandemic has caused a sudden significant 2 increase in hospitalizations for pneumonia with multiorgan disease and has led to more 3 than 300,000 deaths worldwide. COVID-19 is caused by the novel severe acute respiratory 4 syndrome coronavirus 2 (SARS-CoV-2), a novel enveloped RNA betacoronavirus. 5 SARS-CoV-2 infection may be asymptomatic or cause a wide spectrum of symptoms, 6 ranging from mild symptoms of upper respiratory tract infection to life-threatening sepsis. 1 7

Manifestations of COVID-19 include asymptomatic carriers and fulminant disease 8 characterized by sepsis and acute respiratory failure. Approximately 5% of patients with 9 COVID-19, including 20% of those hospitalized, experience severe symptoms 10 necessitating intensive care. More than 75% of patients hospitalized with COVID-19 11 require supplemental oxygen. 1,2 The case-fatality rate for COVID-19 varies markedly by 12 age, ranging from 0.3 deaths per 1000 patients among patients aged 5 to 17 years to 304.9 13 deaths per 1000 patients among patients aged 85 years or older. Among patients 14 hospitalized in the intensive care unit, the case fatality can reach 40%. 1 15

There is currently no human vaccine available for SARS-CoV-2, but approximately 16 120 candidates are under development. In the development of an effective vaccine, a 17 number of challenges must be overcome, such as technical barriers, the feasibility of 18 large-scale production and regulation, legal barriers, the potential duration of immunity 19 and thus the number of vaccine doses needed to confer immunity, and the 20 antibody-dependent enhancement effect. Moreover, there is another complicated area to 21 consider: drug development for COVID-19, especially treatments for patients with severe 22 or late-stage disease. Dexamethasone therapy was reported to reduce 28-day mortality in 23 patients requiring supplemental oxygen compared with usual care (21.6% vs 24.6%; 24 age-adjusted rate ratio, 0.83 [95% CI, 0.74-0.92]) 3 , and remdesivir was reported to 25 improve the time to recovery (hospital discharge or no supplemental oxygen required) 26 from 15 to 11 days. 4 In a randomized trial of 103 patients with COVID-19, convalescent 27 plasma did not shorten the time to recovery 5 . Ongoing trials are testing antiviral therapies, 28 immune modulators, and anticoagulants; however, there is no specific antiviral treatment 29 recommended for COVID-19. 30 ~ 3 ~ Chimeric antigen receptors (CARs) are synthetic receptors that redirect T cell activity 1 towards specific targets 6 . A CAR construct includes antigen-recognition domains in the 2 form of a single-chain variable fragment (scFv) or a binding receptor/ligand in the 3 extracellular domains, a transmembrane domain providing the scaffold and signaling 4 transduction, and intracellular domains from the T cell receptor (TCR) and costimulatory 5 molecules that trigger T cell activation 7 . Based on the longstanding interest in harnessing 6 macrophages to combat tumor growth 8, 9 , human macrophages engineered with CARs have 7 been developed and characterized for their antitumor potential. Macrophages, critical 8 effectors of the innate immune system, are responsible for sensing and responding to 9 microbial threats and promoting tissue repair. We therefore hypothesize that CAR 10 macrophages can be used to combat SARS-CoV-2. However, the hyperinflammatory 11 macrophage response, which has been found to be damaging to the host, particularly in 12 severe infections, including SARS-CoV-2, and cytokine release syndrome (CRS), which is 13 also the most significant complication associated with CAR-T cell therapy, raise questions 14 regarding the safety of using CAR macrophages for virus clearance. 15

In this report, we developed a series of chimeric antigen receptors based on 16 recognition of the S protein and tested their ability to induce phagocytosis of SARS-CoV-2 17 virions. Interestingly, we reported that one CAR with the intracellular domain of MERTK, 18 which belongs to the TAM receptor family, did not show a notable killing effect in 19 antigen-expressing cell-based models compared with other CARs but did demonstrate 20 antigen-specific clearance of SARS-CoV-2 virions in vitro without the secretion of 21 proinflammatory cytokines. 22

To program engulfment based on recognition of the SARS-CoV-2 spike protein, we 24 used a CAR design for the synthetic receptor strategy in our study. The synthetic receptors 25 were constructed to contain an scFv derived from an antibody recognizing the virus spike 26 protein, CR3022, which has been reported to bind with the receptor-binding domain of the 27 SARS-CoV-2 S glycoprotein with high affinity, and the CD8 transmembrane domain 28 present in the αCD19 CAR for T cells 9 . For the cytoplasmic domains, we used the 29 common γ subunit of Fc receptors (CARγ), MEGF10 (CARMEGF10), MERTK (CARMERTK) 30 ~ 4 ~ and CD3ζ (CARζ) in our study (Fig. 1a) . These cytoplasmic domains are capable of 1 promoting phagocytosis by macrophages. 2 Next, we used lentiviral vector technology to express the fusion constructs in human 3 macrophage THP-1 cells using clinically validated techniques 10 . The cDNA sequences 4 containing the various fusion constructs were cloned into a third-generation lentiviral 5 vector in which the CMV promoter was replaced with the EF-1α promoter 11 . An 6 extracellular MYC epitope was cloned into the receptors to permit detection by flow 7 cytometry. Lentiviral vector supernatants transduced THP-1 cells with high efficiency (Fig.  8 1b). The phagocytic potential of human macrophage THP-1 cell lines expressing different 9 CAR receptors or a truncated CAR receptor (CARΔ) lacking the intracellular domain was 10 measured with a cell-based assay. Consistent with previous reports 8, 9 , CAR macrophages 11 and control untransduced (UTD) macrophages did not show notable phagocytosis of 293 12 cells; however, CARMEGF10, CARγ and CARζ cells but not CARMERTK, CARΔ, or UTD 13 macrophages phagocytosed Spike-bearing 293 cells in an S-specific manner (Fig. 1c) . 14 CAR-mediated macrophage phagocytosis was further confirmed by a luciferase-based 15 killing assay, and our data showed that CARMEGF10, CARγ and CARζ cells eradicated S 16 protein-expressing 293T cells in an antigen-specific manner (Fig. 1d) . Interestingly, 17 CARMERTK and UTD macrophages showed-no difference in killing effect. Our data further 18 showed that all synthetic receptors had the ability to bind the S protein (Fig. 1e) ; therefore, 19 the differences in phagocytosis and the lytic effect were not due to the affinity for the S 20

Although there is currently no evidence that SARS-CoV-2 can infect THP-1 cells with 22 or without IgGs 12 , THP-1 cells have been shown to support antibody-mediated 23 enhancement of SARS-CoV infection in previous studies 13 . We therefore sought to 24 determine whether synthetic receptors facilitate the entry of SARS-COV-2 into 25 macrophages as host cells, as the extracellular domain of the CAR constructs has the 26 capacity to directly bind to the S protein. Replication-defective VSV particles bearing 27 coronavirus S proteins faithfully reflect key aspects of host cell entry by coronaviruses, 28

including SARS-CoV-2 14,15 . We therefore employed VSV pseudotypes bearing SARS-2-S 29 to study the cell entry of SARS-CoV-2. Our data showed that Vero E6 cells were 30 susceptible to entry driven by SARS-S (Fig. 2a) ; however, no evidence of infection was 31 ~ 5 ~ detected in THP-1 cells with or without synthetic receptors. 1 Antibody-mediated phagocytosis and internalization of virions are important 2 mechanisms of antiviral activity performed by macrophages against pathogens; however, 3 using the phagocytosis assay developed for SARS-CoV-2, we observed low levels of 4 phagocytic activity when UTD cells directly contacted virions. Phagocytic activity was not 5 significantly increased when CARΔ cells rather than UTD macrophages were the 6 phagocytes in the assay, suggesting that the extracellular domain of the CAR alone is not 7 sufficient to induce strong virion internalization. CARγ, CARMEGF10, and CARζ mediated 8 similar significantly stronger levels of SARS-CoV-2 phagocytosis by THP-1 cells than 9 CARΔ (Fig 2b) . Unexpectedly, we also observed strong internalization of virions in 10 CARMERTK cells, which did not show specific phagocytic or lytic effects on S 11 protein-expressing 293T cells. Since all the CARs exhibited the ability to induce 12 phagocytosis of SARS-CoV-2 virions while there was no evidence of infection, these 13 experiments strongly suggest the clearance of SARS-CoV-2 virions of CAR macrophages. 14 Because the systemic cytokine profiles observed in patients with severe COVID-19 15

show similarities to those observed in patients with macrophage activation syndrome, 16 culture supernatants from THP-1 cells with different CARs treated with virions were 17 further analyzed in a multiplex cytokine assay (Fig. 2c) . Following SARS-CoV-2 treatment 18 of THP-1 cells, we observed slightly increased secretion of the cytokines IL-6, IL-8 and 19

TNF-α, but no discernable patterns could be confidently drawn for GM-CSF, IL-1β, IL-2, 20 IL-4, IL-5, IL-8, IL-10, and IFN-γ. CARΔ cells showed a cytokine profile similar to that of 21 UTD macrophages. Notably, we observed not only strongly increased induction of IL-6, 22

IL-8 and TNF-α but also induction of IFN-γ and IL-10 in SARS-CoV-2-treated CARγ and 23

CARζ cells. However, for CARMERTK cells, we did not observe significant changes in 24 cytokines. 25

We further used a transwell-based coculture model to evaluate the protective role of 26 CAR macrophages in SARS-CoV-2 infection (Fig. 3a) . All the CAR-expressing 27 macrophages potently inhibited Vero E6 cell infection with the SARS-CoV-2-S 28 pseudotyped virus. Interestingly, CARΔ cells showed no protective effect in the infection 29 assay, although they had a similar capacity to bind to the S protein, suggesting that the 30 intracellular signaling domain is necessary for virion clearance by CAR macrophages ( TNF-α, IFN-γ and IL-10 was significantly elevated in CARγ and CARζ cells treated with 2 SARS-CoV-2 virions, suggesting that these CAR macrophages may not be suitable for 3 application in severe patients or patients with late-stage COVID- 19. 4 Previous studies have shown that human immune cells, such as THP-1 cell lines, are 5 susceptible to SARS-CoV infection 24 . We did not observe any evidence that our 6 SARS-CoV-2 pseudotyped virus infected THP-1 cells. Moreover, the uptake of virions by 7 THP-1 cells was very low, even with a truncated CAR with the ability to bind to the S 8 protein, suggesting that THP-1 cells did not innately engulf the virions. Notably, 9

CARMERTK, which was regarded as an unsuccessful receptor in a previous report 8 PtdSer-dependent process termed "apoptotic mimicry" and act as potent TAM agonists, in 27 turn inhibiting the type I IFN response in target cells 27 . In our study, THP-1 cells 28 expressing the synthetic receptor with the MERTK cytoplasmic domain were relatively 29 resistant to virus infection but induced notable virion clearance. It should be noted that our 30 study used very simple infection models; therefore, the assays lack numerous physiological 31 ~ 8 ~ and pathological factors, such as IgG or complement-mediated immune complexes, that 1 may interfere with the behavior of engineered cells. Of cause, cells expressing synthetic 2 receptors can be further engineered and developed to achieve precise control. 3

In summary, our data reveal that the CAR-based synthetic approach is applicable for 4 COVID-19 treatment. In addition to direct virion clearance by CAR macrophages, we 5 found evidence that MERTK-based CAR receptors did not induce further upregulation of 6 proinflammatory cytokine levels, thereby raising the possibility that CAR macrophages 7 may be useful as potent therapeutics in severe COVID-19. The sequence encoding the scFv generated from CR3022 was chemically synthesized. 20

As shown in Fig. 1a , synthetic receptors contained the human CD8α signal peptide 21 followed by the scFv linked in-frame to the hinge domain of the CD8α molecule, 22 transmembrane region of the human CD8 molecule, and intracellular signaling domains of 23 the FCER1G, MEGF10, MERTK or CD3ζ molecules. The fragments were subcloned into 24 the pELNS vector 28 . High-titer replication-defective lentiviruses were produced and 25 concentrated 28 . Lentiviral infection was used to stably express CAR constructs in THP-1 26

UTD or CAR-expressing THP-1 cells were cocultured with GFP + 293T cells or GFP + 29 293T-S (S + ) target cells for 4 h at 37 °C. The effector-to-target (E:T) ratio was 1:1, and 1 × 30 1 harvested and stained with an anti-CD11b APC-Cy7-conjugated antibody (M1/70, 2 BioLegend) and analyzed by FACS using a FACSCalibur flow cytometer (BD 3 Biosciences). The percentage of phagocytosis was calculated based on the percent of GFP + 4 events within the CD11b + population. Data are represented as the mean ± standard error of 5 quadruplicate wells. 6

Cell-surface staining was performed for 45 min at 4 °C and was analyzed using a 8

FACSCalibur flow cytometer (BD Biosciences). A minimum of 1 × 10 4 events per sample 9 were examined. 10

293T and 293T-S cells were used as targets in luciferase-based killing assays including 12 control (UTD) or CAR macrophages. The effector-to-target (E:T) ratio was 10:1 for all the 13 groups. Bioluminescence was measured using a Bio-Tek Synergy H1 microplate reader. 14 The percent specific lysis was calculated on the basis of the experimental luciferase signal 15 (total flux) relative to the signal of the target alone, using the following formula: %Specific In all cases, SARS-CoV-2 S pseudotyped virions were pelleted (90 min at 14,000 rpm 2 and 4 °C), and after removal of the supernatant, the pellets were resuspended in RPMI 3 medium and incubated with phagocytes (THP-1 cells or CAR macrophages) at 37 °C for 4 1.5 h. After allowing time for phagocytosis, the cells were washed three times with PBS 5 and incubated with Accutase (Innovative Cell Technologies) for 10 min at 37 °C, followed 6 by a final wash in Accutase. Intracellular staining for the S protein was performed for 60 7 min on ice after using a fixation/permeabilization kit (eBioscience) and then analyzed 8 using a FACSCalibur flow cytometer (BD Biosciences). The phagocytic score was 9 determined by gating the samples on events representing cells and was calculated as 10 follows: Percent S protein positive × median fluorescence intensity (MFI). 11

Cytokine analysis was performed on supernatants derived from cultures given the 13 indicated treatments using a human cytokine 10-plex panel (Thermo Scientific) per the 14 manufacturer's instructions, with the panel results read on a Luminex Analyzer. 15

Unless otherwise specified, Student's t test was used to evaluate the significance of 17 differences between two groups, and ANOVA was used to evaluate differences among 18 three or more groups. Differences between samples were considered statistically 19 significant when P < 0.05. The results shown represent three (b) independent experiments. Data are the shown as the 2 mean ± s.d. of four independent biological replicates (c, d, e). P values were derived by 3 one-way ANOVA followed by Tukey's posttest (c, d, e). *p<0.05, **p<0.01, ***p<0.001, 4 ****p<0.0001. 5 or two-way ANOVA followed by the Bonferroni posttest (c); *p<0.05, **p<0.01, 20 ***p<0.001, ****p<0.0001. 21 independent biological replicates. P values were derived by one-way ANOVA followed by 28

Tukey's posttest. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 29

A Review

Hospitalization Rates and Characteristics of Patients Hospitalized with 5

Coronavirus Disease 2019 -COVID-NET, 14 States

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

CAR T cell 14 immunotherapy for human cancer

Engineered T cells: the promise and challenges of cancer 16 immunotherapy

Chimeric antigen receptors that trigger phagocytosis

Human chimeric antigen receptor macrophages for cancer immunotherapy

Gene transfer in humans using a conditionally replicating lentiviral vector

CAR exosomes derived from effector CAR-T cells have potent antitumour effects and 23 low toxicity

Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute 25 Respiratory Syndrome Coronavirus 2

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger 27 infection of human immune cells via a pH-and cysteine protease-independent FcγR pathway

Mutations in the spike protein of Middle East respiratory syndrome 30 coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a 33 clinically proven protease inhibitor

The Lung Macrophage in SARS-CoV-2 35 Infection: A Friend or a Foe?

Viral Targets and Reservoirs

In the eye of the COVID-19 cytokine storm

In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian 42 carcinoma

CAR T cell-induced cytokine release syndrome is mediated by macrophages and 44 abated by IL-1 blockade

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 46 The lancet 395

Clinical and immunological features of severe and moderate coronavirus disease 48 2019

Pathological inflammation in patients with COVID-19: a key role for 50 monocytes and macrophages

Modeling the early events of severe acute respiratory syndrome coronavirus 52 infection in vitro

The TAM family: This study was supported by the National Natural Science Foundation of China (grant nos

Program (grant no. 19QA1411400); and the Shanghai Sailing Program

Competing Interests: the authors declare the following competing interests